Completed × Carcinoma, Non-Small-Cell Lung × Erlotinib Hydrochloride × Clear all A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
92 enrolled 14 charts
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Phase 1 Completed
8 enrolled
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Phase 2 Completed
88 enrolled
BM
Phase 2/3 Completed
492 enrolled
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Phase 2 Completed
17 enrolled 9 charts
DELINOR
Completed
5,279 enrolled 10 charts
EURTAC
Phase 3 Completed
174 enrolled 20 charts
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1/2 Completed
11 enrolled 11 charts
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Phase 1/2 Completed
40 enrolled 21 charts
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
Phase 1 Completed
26 enrolled
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase 1 Completed
95 enrolled
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase 2 Completed
647 enrolled 17 charts
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
Phase 1 Completed
50 enrolled
BLISS
Phase 2 Completed
154 enrolled
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
Phase 1/2 Completed
31 enrolled
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
123 enrolled 11 charts
UpSwinG
Completed
462 enrolled 23 charts
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Phase 1 Completed
43 enrolled
MK-3475-021
Phase 1/2 Completed
267 enrolled 24 charts
BELIEF
Phase 2 Completed
109 enrolled 20 charts
NSCLC
Phase 2 Completed
32 enrolled 8 charts
SLAT
Phase NA Completed
153 enrolled
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase 2 Completed
166 enrolled 11 charts
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
334 enrolled 14 charts
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
Phase 1 Completed
35 enrolled
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Phase 1 Completed
472 enrolled 26 charts
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Phase 2 Completed
44 enrolled 16 charts
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Completed
222 enrolled 23 charts
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Phase 1 Completed
15 enrolled 14 charts
CheckMate370
Phase 1/2 Completed
341 enrolled 28 charts
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Phase 2 Completed
201 enrolled 12 charts
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1 Completed
17 enrolled 12 charts
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase 3 Completed
636 enrolled 14 charts
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
Phase 1 Completed
248 enrolled
TARLAL
Phase 2 Completed
15 enrolled 6 charts
NVALT10
Phase 2 Completed
195 enrolled
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
79 enrolled 13 charts
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
24 enrolled 12 charts
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
32 enrolled 13 charts
Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Phase 1 Completed
24 enrolled
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Completed
52 enrolled
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
Phase 2 Completed
82 enrolled
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Phase 2 Completed
84 enrolled 15 charts
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Phase 2 Completed
89 enrolled 11 charts
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
59 enrolled 13 charts
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
37 enrolled 9 charts
OSI-774 (Erlotinib, Tarceva) in Elderly Patients
Phase 2 Completed
30 enrolled
ESSENCE
Phase 3 Completed
375 enrolled 12 charts
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Phase 2 Completed
84 enrolled 12 charts
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
68 enrolled 11 charts